Home / Poster / Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia

海报

GalNAc-siRNA 偶联物 Plozasiran（ARO-APOC3）在混合性高脂血症患者动脉粥样硬化性心血管疾病（ASCVD）潜在治疗中的群体药代动力学-药效学（K-PD）建模

GalNAc-siRNA 偶联物 Plozasiran（ARO-APOC3）在混合性高脂血症患者动脉粥样硬化性心血管疾病（ASCVD）潜在治疗中的群体药代动力学-药效学（K-PD）建模

相关推荐

Quantitative Systems Pharmacology Conference

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Milliliters, Milligrams, and Moles: Keeping Up with Units in NCA

网络研讨会

Non-compartmental analysis of statin pharmacokinetics in pharmacogenetics research

网络研讨会

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software